# Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor

> **NCT07203846** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Collegium Medicum w Bydgoszczy** · enrollment: 50 (estimated)

## Conditions studied

- ACS - Acute Coronary Syndrome
- Ticagrelor
- Microbiota
- Platelet Aggregation
- Myocardial Infarction (MI)
- Blood Platelets
- Drug Effects
- Platelet Aggregation Inhibitors
- Drug Resistance
- Platelet Function Tests
- Dysbiosis
- Anti-Bacterial Agents
- Rifaximin

## Interventions

- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT07203846
- **Lead sponsor:** Collegium Medicum w Bydgoszczy
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07203846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07203846, "Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07203846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*